Genmab's Rina-S improves survival in Phase 3 ovarian cancer trial
GMAB•Genmab said its investigational Rina-S improved progression-free and overall survival versus chemotherapy in the Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer. No new safety signals or unexpected safety concerns emerged.
1. Trial results
Rina-S improved progression-free survival versus chemotherapy, and overall survival also improved significantly. Genmab said benefits were clinically meaningful across both trial analysis populations, with no new safety signals or unexpected safety concerns. Results will be submitted for presentation at a future medical meeting, and regulatory discussions are planned worldwide.
